Skip to main content
Premium Trial:

Request an Annual Quote

Perlegen Wins $1.66M in FY 05 from NIAID to Map SNPs of Plague Bacterium and Relative

NEW YORK, April 4 (GenomeWeb News) - Perlegen Sciences has won a two-year biodefense partnership grant from the National Institute of Allergy and Infectious Diseases to genotype the plague bacterium and a related species, the company said today.


In collaboration with scientists at Lawrence Berkeley National Laboratory, Perlegen will use its oligo array technology to genotype the genomes of approximately 150 strains of Yersinia pestis, which causes the plague, and Yersinia pseudotuberculosis, a closely related bacterium.


The aim is to discover a genome-wide set of SNPs that will help to distinguish different strains and understand their biology. Perlegen plans to make the SNPs publicly available through dbSNP and othr websites.


The amount of the grant was not immediately available from Perlegen, but NIH databases list a two-year grant to Perlegen in 2005 entitled "Signature SNPs to Distinguish Yersinia Pestis Strains" with an award of $1.66 million in fiscal year 2005.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.